Despite early failures in the clinic, the idea of anti-aging therapies that purge the body of dying cells is gaining traction with a raft of startups now focused on senescence.
Valuable review describing the emerging field of therapeutic development targeting senescence biology to treat age-related conditions.
Join us at LT2021. Rubedo will be contributing with a lecture and a round table.
Rubedo Life Sciences CEO, Dr. Marco Quarta, will join the Panel Discussion titled
A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities
Moreover, Dr. Quarta will give a lecture on Higher selectivity and safety of Targeted Senolytcs
Salaried internship opportunities at Rubedo Life Sciences for 2021-2022
9 month internship – CalPoly CIRM Master Program for Regenerative Medicine
Summer Internship – SENS Research Foundation Program
Rubedo Life Sciences presents results from its strategy of engineered small molecules to target senescence cells in chronic diseases at Ending Age-Related Diseases Conference
Rubedo Life Sciences CEO, Dr. Marco Quarta presents the novel targeted senolytic program based on Rubedo engineered small molecules
Rubedo Life Sciences is represented by CEO, Dr. Marco Quarta, at the National Institute of Aging of the National Institute of Health (NIA-NIH) Geroscience Summit titled: “Targeting Chronic Diseases Through Geroscience“
By James Gallagher
Health and science reporter, BBC News website
Findings raise possibility that a future therapy that rids the body of senescent cells might protect against the ravages of old age
Silicon Valley, CA, USA
Copyright 2020 by Rubedo Life Sciences, inc
